Managing hematological toxicity in [¹⁷⁷Lu]Lu-DOTATATE for NET patients: a national survey from the French group of endocrine tumors (GTE) on the clinical need for harmonized monitoring strategies
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8719-8722
DOI: 10.1007/s00259-026-08118-4 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 10.08.2026. Verfasst von S Oziel-Taieb und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut Paoli Calmettes, ENETS Center of Excellence, IPCNET Center, Marseille, France. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Organometallic Compounds. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Peptide receptor radionuclide therapy (PRRT) with [¹⁷⁷Lu]Lu-DOTATATE is a standard treatment for metastatic neuroendocrine tumors (NET), but management of hematological toxicity beyond the thresholds defined in the Summary of Product Characteristics (SmPC) relies heavily on individualized clinical judgment. To characterize real-world practices, we conducted a national anonymous survey among French nuclear medicine physicians and medical oncologists involved in PRRT, under the auspices of the SFMN, GTE, and ENDOCAN-RENATEN network. Forty expert physicians completed the 45-item LutaViRe questionnaire. Results show that clinicians frequently apply higher platelet thresholds than the SmPC minimum, adjust first-cycle activity, and rely on individualized, often multidisciplinary strategies when facing acute or persistent thrombocytopenia. Nutritional deficiency screening and structured long-term hematological monitoring, including for therapy-related myeloid neoplasms, remain insufficiently implemented. These findings reveal substantial heterogeneity in the real-world hematological management of [¹⁷⁷Lu]Lu-DOTATATE and support the development of harmonized, individualized monitoring guidelines integrating patient risk profiles and systematic pharmacovigilance reporting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Institut Paoli Calmettes, ENETS Center of Excellence, IPCNET Center, Marseille, France.
- Nantes Université, Univ Angers, CHU Nantes, Inserm, CNRS, CRCI2NA, Médecine Nucléaire, Nantes, F-44000, France.
- Department of Nuclear Medicine, Haut-Lévêque Hospital, University Hospital of Bordeaux, Pessac, France.
- Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Inserm U1194, Montpellier, France.
- Department of Medical Oncology, Institut Paoli Calmettes, ENETS Center of Excellence, IPCNET Center, Marseille, France. magalie.haissaguerre@chu-bordeaux.fr.
- Nantes Université, Univ Angers, CHU Nantes, Inserm, CNRS, CRCI2NA, Médecine Nucléaire, Nantes, F-44000, France. magalie.haissaguerre@chu-bordeaux.fr.
ORCID-Profile: M Haissaguerre
Zitieren
APA
Oziel-Taieb, S., Ansquer, C., Tlili, G., Deshayes, E., & Haissaguerre, M. (2026). Managing hematological toxicity in [¹⁷⁷Lu]Lu-DOTATATE for NET patients: a national survey from the French group of endocrine tumors (GTE) on the clinical need for harmonized monitoring strategies. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8719-8722. https://doi.org/10.1007/s00259-026-08118-4
Vancouver
Oziel-Taieb S, Ansquer C, Tlili G, Deshayes E, Haissaguerre M. Managing hematological toxicity in [¹⁷⁷Lu]Lu-DOTATATE for NET patients: a national survey from the French group of endocrine tumors (GTE) on the clinical need for harmonized monitoring strategies. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8719-8722. doi:10.1007/s00259-026-08118-4
BibTeX
@article{OzielTaieb2026,
author = {Oziel-Taieb, S and Ansquer, C and Tlili, G and Deshayes, E and Haissaguerre, M},
title = {Managing hematological toxicity in [¹⁷⁷Lu]Lu-DOTATATE for NET patients: a national survey from the French group of endocrine tumors (GTE) on the clinical need for harmonized monitoring strategies},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8719--8722},
doi = {10.1007/s00259-026-08118-4}
}
EUVIMED